Overview
CJC-1295 No DAC combined with Ipamorelin represents a well-established research pairing in growth hormone axis studies. CJC-1295 No DAC is a growth hormone releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone releasing peptide (GHRP). Together they target two distinct points of the GH secretion pathway, making this blend a valuable tool for studying synergistic GH axis stimulation.
CJC-1295 No DAC + Ipamorelin is planned for the Indonesia catalogue. Register for availability updates.
Key Research Areas
GH Axis Synergy Research
The GHRH + GHRP combination allows researchers to study the amplified GH secretion response when both pathways are stimulated simultaneously versus each compound in isolation.
Pituitary Somatotroph Studies
Both peptides act on pituitary somatotroph cells — CJC-1295 via GHRH receptors and Ipamorelin via ghrelin receptors — enabling detailed study of pituitary GH release mechanisms.
IGF-1 Signalling Research
GH axis stimulation downstream affects IGF-1 production in hepatic models, making this combination useful for studying the GH/IGF-1 axis in cell studies.
Selective GHRP Pharmacology
Ipamorelin's high selectivity for the ghrelin receptor without significant cortisol or prolactin effects makes it a cleaner GHRP research tool compared to earlier generation compounds.
Product Specifications
| Format | Lyophilised powder blend |
| Quantity | Blended vial (CJC-1295 No DAC + Ipamorelin) |
| Purity | >98% (HPLC verified) |
| Storage | Refrigerate at 2–8°C. Stable 24 months lyophilised. |
| Research use | In vitro / laboratory use only |
| Availability | Launching Soon |
Quality documentation
Testing documents must match the product and batch supplied. We do not present a generic report as proof for every batch.
See our testing policy and request a batch report →